- Phase 1a Safety and Preliminary Efficacy Results to be Presented -

IRVINE, CA / ACCESSWIRE / May 15,2019 / TRIGR Therapeutics, Inc. ('TRIGR'), a clinical stage biotechnology company focused on the development of multi-targeted and immunomodulatory bispecific antibodies, and ABL Bio Corporation ('ABL Bio') (298380.KS), a South Korean biotechnology company, announced that new clinical data will be presented at the 2019 American Society of Clinical Oncology (ASCO) annual meeting to be held May 31st to June 4th, 2019 in Chicago. Abstracts are available online to the public on the ASCO website: http://abstracts.asco.org/.

The poster presentation will include Phase 1a study results including safety and preliminary efficacy data of TR009 (ABL001, NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer. The study is sponsored by ABL Bio and National OncoVenture (NOV), a South Korean government funded oncology drug development program. TRIGR holds an exclusive and global development and commercialization license from ABL Bio for all oncology indications, excluding the Republic of Korea.

The details of the presentation are as follows:

About TRIGR Therapeutics

TRIGR (www.TrigrRx.com) is an emerging biotechnology company in the field of next generation cancer therapies that was incorporated in April 2018 and managed by biopharmaceuticals industry veterans. TRIGR focuses on clinical development and commercialization of targeted and immuno-modulatory drugs with validated mechanism of action and novel formats for the US, European and Asian markets. The Company's pipeline includes a clinical stage dual-angiogenesis bispecific antibody program (TR009) and pre-clinical dual checkpoint and immune engaging bispecific antibodies. http://www.trigrrx.com/.

George Uy, CEO & Founder, [email protected]

Miranda Toledano, COO/CFO, [email protected]

About ABL Bio

ABL Bio (298380:KS) is a South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. Founded in 2016, ABL Bio successfully raised close to $170 million USD in 3 years and listed on the Korean stock exchange (KOSDAQ) in December 2018. ABL001 (NOV1501, TR009), a bispecific antibody (BsAb) targeting VEGF and DLL4 is currently in Phase 1 clinical trial for oncology. ABL Bio is also actively developing multiple 4-1BB based T cell engaging bispecific antibodies and several innovative First-in-Class and Best-in-Class bispecific antibody-based immunotherapies. In the neurodegenerative disorder space, ABL Bio is harnessing its BsAb expertise to develop next-generation BsAbs designed to maximize blood-brain barrier (BBB) penetration and therapeutic efficacy. The most advanced molecule is ABL301, an α-synuclein-targeting BsAb that penetrates the BBB via a receptor-mediated transcytosis (RMT) and is in development for Parkinson's disease (PD). For more information, check out www.ablbio.com.

SOURCE: TRIGR Therapeutics, Inc.